

## **QUANTEL MEDICAL'S OPTIMIS FUSION™ RECEIVES CE MARK**

*Combination Laser Platform Includes SLT, YAG for Treatment of Glaucoma and Cataract*

**Clermont-Ferrand, France – January 27, 2014** – Quantel Medical today announced CE Mark approval for its **Optimis Fusion™** integrated laser platform. The Fusion system combines advanced selective laser trabeculoplasty (SLT) photoregeneration therapy and traditional YAG photodisruption treatments to offer ophthalmologists a versatile armamentarium for treating both cataract and glaucoma. Quantel will immediately begin commercialization in all CE Mark-approved countries. FDA approval is expected in 2014.

The Fusion's unique SLT mode incorporates the most advanced laser technology available to provide a first-choice treatment for managing glaucoma and lowering intraocular pressure. SLT therapy targets melanin-rich cells, which absorb the laser energy to induce a healing response that begins to improve the function of the trabecular meshwork. The laser energy is delivered in short, fixed pulses over a large, homogeneous spot size, resulting in no thermal damage. Due to the gentle delivery and no permanent destruction to the trabecular meshwork, SLT leaves the structures intact and can be repeated if necessary.

The YAG mode delivers high-performance photodisruption for capsulotomy and peripheral iridotomy. The gaussian laser beam profile allows for precise laser delivery at minimum energy levels, avoiding side effects such as lens pitting. Precise tissue targeting is achieved with the advanced two-point aiming beam, allowing for fast and accurate targeting of the capsule, and an adjustable anterior and posterior offset feature allows for easy focus adjustment in front of, behind, or at the point of disruption.

"This approval constitutes a critical milestone for our medical laser business," said **Jean-Marc Gendre**, CEO of Quantel Medical. "We are proud to introduce an engineering breakthrough, which enables infrared and visible green nanosecond pulses to be produced by a single dual-mode cavity, reducing complexity and resulting in a more elegant and up-to-date combo laser design. Through our engineering expertise, we continue to provide the most advanced laser solutions to the market."

In addition to this world-class SLT and YAG combination laser, the Fusion integrates smoothly with Quantel's Vitra™ Monospot and Multispot pattern-scanning retina laser systems, offering comprehensive treatment options for multi-specialty practices to treat glaucoma, cataract and retina conditions in one laser platform.

### **About Quantel Medical**

Founded in 1993 and headquartered in Clermont-Ferrand, France, Quantel Medical is a global ophthalmic medical device company dedicated to developing leading technologies to improve the treatment of ocular diseases. Quantel Medical has a strong emphasis in research and development, resulting in many first-to-market product introductions and a comprehensive product portfolio of diagnostic ultrasound and surgical lasers for ophthalmologists. These products are available through direct sales operations in the U.S. and France, and through independent distributors in over 80 countries.

Quantel Medical is a division of Quantel (QUA:EN), a world-wide leader in the development of solid-state lasers for scientific and industrial applications. For more information, please visit [www.quantel-medical.com](http://www.quantel-medical.com).